Neuro-Oncology News

CHICAGO — SurVaxM demonstrated encouraging efficacy and immunogenicity among patients with newly diagnosed glioblastoma, according to results of a multicenter, single-arm phase 2 clinical trial presented at ASCO Annual Meeting.

CHICAGO — Proton chemoradiotherapy significantly reduced incidence of adverse events associated with unplanned hospitalizations compared with traditional photon chemoradiotherapy among adults with nonmetastatic cancers, according to results of a comparative effectiveness study presented at ASCO Annual Meeting.

For all cancer types, U.S. mortality rates continued to decline among adults and children from 1999 to 2016, with decreasing incidence rates for men and stable incidence rates for women, according to the Annual Report to the Nation on the Status of Cancer.

A 24-year-old Guyanese man presented with a 3-month history of personality changes, abulia, headaches, nausea and vomiting.

Survivors of allogeneic hematopoietic cell transplantation who underwent high-dose total body irradiation incurred nearly eight times the risk for subsequent malignant neoplasms compared with the general population, according to study results published in Blood.

Comprehensive molecular profiling feasibly identified potentially actionable mutations among children and adolescents with hard-to-treat cancers, according to results of a prospective study published in JAMA Network Open.

Genetic sequencing of tumors among children with refractory cancer led to about a quarter of those tested being matched with therapies targeting their specific genetic alteration, according to results of a study scheduled for presentation at ASCO Annual Meeting.

Children with central nervous system or other solid tumors with specific gene fusions responded to treatment with the investigational tyrosine kinase inhibitor entrectinib, according to results of a phase 1/1b trial scheduled for presentation at ASCO Annual Meeting.

Children with high-risk neuroblastoma derived excellent outcomes from proton radiation therapy with minimal toxicity, according to results of the largest-ever cohort study of its kind published in International Journal of Radiation Oncology Biology Physics.

Researchers at Stanford University School of Medicine have used chimeric antigen receptor T cells targeting B7-H3 to attack certain solid tumors in several pediatric cancer models.